DE69226197T2 - Hämoglobine als arzneimittelabgabesystem - Google Patents
Hämoglobine als arzneimittelabgabesystemInfo
- Publication number
- DE69226197T2 DE69226197T2 DE69226197T DE69226197T DE69226197T2 DE 69226197 T2 DE69226197 T2 DE 69226197T2 DE 69226197 T DE69226197 T DE 69226197T DE 69226197 T DE69226197 T DE 69226197T DE 69226197 T2 DE69226197 T2 DE 69226197T2
- Authority
- DE
- Germany
- Prior art keywords
- hemoglobine
- delivery system
- medicine delivery
- hemoglobin
- tracer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78917791A | 1991-11-08 | 1991-11-08 | |
| US07/789,179 US5545727A (en) | 1989-05-10 | 1991-11-08 | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
| PCT/US1992/009713 WO1993008842A1 (en) | 1991-11-08 | 1992-11-06 | Hemoglobins as drug delivery agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69226197D1 DE69226197D1 (de) | 1998-08-13 |
| DE69226197T2 true DE69226197T2 (de) | 1999-02-11 |
Family
ID=27120889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69226197T Expired - Lifetime DE69226197T2 (de) | 1991-11-08 | 1992-11-06 | Hämoglobine als arzneimittelabgabesystem |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5679777A (de) |
| EP (1) | EP0611306B1 (de) |
| JP (1) | JP3426599B2 (de) |
| AT (1) | ATE168014T1 (de) |
| AU (1) | AU665599B2 (de) |
| CA (1) | CA2122717C (de) |
| DE (1) | DE69226197T2 (de) |
| WO (1) | WO1993008842A1 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
| JP3426599B2 (ja) * | 1991-11-08 | 2003-07-14 | ヘモゾル インコーポレイテッド | 薬物担体としてのヘモグロビン |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP0804244A1 (de) * | 1993-03-26 | 1997-11-05 | Biorelease Technologies, Inc. | Häm-proteine enthaltende zusammensetzungen und dazu gehörende methoden |
| US5665869A (en) * | 1993-11-15 | 1997-09-09 | Somatogen, Inc. | Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin |
| US6458762B1 (en) | 1994-03-28 | 2002-10-01 | Baxter International, Inc. | Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis |
| US5670347A (en) | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP1950298A3 (de) | 1997-05-02 | 2008-12-24 | Baxter Biotech Technology S.A.R.L. | Hämoglobinmutanten mit erhöhtem Löslichkeitswert und/oder reduzierter Stickoxidspülung |
| PT1001978E (pt) * | 1997-06-24 | 2005-08-31 | Proteus Molecular Design | Derivados da angiotensina |
| US7378489B1 (en) | 1999-12-23 | 2008-05-27 | Protherics Medicines Development Limited | Angiotensin derivatives |
| US20050059576A1 (en) * | 1998-04-30 | 2005-03-17 | Adamson J. Gordon | Targeted delivery of antiviral compounds through hemoglobin bioconjugates |
| CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| US6706759B1 (en) | 1998-09-08 | 2004-03-16 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
| US7816403B2 (en) * | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
| US6589987B2 (en) | 1998-09-08 | 2003-07-08 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using tetraethyl thiuram disulfide |
| US6548540B2 (en) | 1998-09-08 | 2003-04-15 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
| US6706252B1 (en) | 1998-10-30 | 2004-03-16 | Rx/Ibr Corporation | Method of treating disease with radioisotopes conjugated to bioactive substances |
| DE19926475A1 (de) | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| DE60030323T2 (de) * | 1999-12-24 | 2007-10-11 | Genentech, Inc., South San Francisco | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
| JP2003522806A (ja) | 2000-02-15 | 2003-07-29 | ジェンザイム、コーポレーション | 改良された薬物送達のための生体高分子の修飾 |
| US6749865B2 (en) | 2000-02-15 | 2004-06-15 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
| EP1274720A4 (de) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Albumin enthaltende fusionsproteine |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2002332041A1 (en) * | 2001-10-05 | 2003-04-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| GB0125793D0 (en) * | 2001-10-26 | 2001-12-19 | Panzeri Ezio | Method |
| EP2277888A3 (de) | 2001-12-21 | 2011-04-27 | Human Genome Sciences, Inc. | Fusionsprotein von Albumin und Erythropoietin |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7235639B2 (en) | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| WO2006041641A2 (en) * | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Therapeutic agents with decreased toxicity |
| EP1814573B1 (de) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
| NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| DE102006011660A1 (de) * | 2006-03-12 | 2007-09-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Ermittlung einer Dotierungsdichte in einer Halbleiterprobe |
| JP2009544327A (ja) | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー／エス | Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化 |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
| EP2479189B1 (de) | 2006-12-12 | 2015-02-25 | Biorexis Pharmaceutical Corporation | Transferrin-Fusionsproteinbibliotheken |
| KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법 |
| JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | ヌクレオチド糖の改良製造法 |
| KR20100051722A (ko) * | 2007-08-20 | 2010-05-17 | 엔즌 파마슈티칼스, 인코포레이티드 | 피리딜 이황화 부분을 포함하는 폴리머 링커 |
| CN103497246B (zh) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
| US8436140B2 (en) * | 2008-06-02 | 2013-05-07 | Washington University | Natriuretic peptide-mediated imaging of atherosclerotic plaque |
| ES2935573T3 (es) | 2011-10-07 | 2023-03-08 | Epicentrx Inc | Compuestos de organonitro tioéter y usos médicos de estos |
| US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| EP2872154B1 (de) * | 2012-07-11 | 2017-05-31 | Sangamo BioSciences, Inc. | Verfahren und zusammensetzungen zur freisetzung von biologischen wirkstoffen |
| US9636404B2 (en) * | 2013-05-13 | 2017-05-02 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| PL412787A1 (pl) | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| KR20190040931A (ko) | 2016-01-11 | 2019-04-19 | 에피센트알엑스, 인코포레이티드 | 2-브로모-1-(3,3-디니트로아제티딘-1-일)에타논의 정맥내 투여를 위한 조성물 및 방법 |
| WO2017197499A1 (en) * | 2016-04-25 | 2017-11-23 | The Governing Council Of The University Of Toronto | Stabilized hemoglobin-avidin assembly and method of preparation |
| US20230190947A1 (en) * | 2016-06-21 | 2023-06-22 | Therapure Biopharma Inc. | Hemoglobin-Targeted Drug Delivery For The Treatment of Cancer |
| EP3526195A4 (de) | 2016-10-14 | 2020-05-20 | EpicentRx, Inc. | Sulfoxyalkylorganonitro- und verwandte verbindungen und pharmazeutische zusammensetzungen zur verwendung in der medizin |
| SG11201907358RA (en) * | 2017-02-08 | 2019-09-27 | Hkl Medical Llc | Intrasite administration and dosing methods and pharmaceuticals for use therein |
| CN111511350B (zh) | 2017-07-07 | 2023-10-13 | 埃皮辛特瑞柯斯公司 | 用于治疗剂的肠胃外施用的组合物 |
| US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
| EP3650046A1 (de) | 2018-11-08 | 2020-05-13 | Cellis AG | System auf basis mesenchymaler stammzellen zur gezielten wirkstoffabgabe |
| WO2024056413A1 (en) | 2022-09-13 | 2024-03-21 | Cellis Ag | Isolated targeted delivery system for the treatment of glioma |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3934008A (en) * | 1968-08-23 | 1976-01-20 | Ciba-Geigy Corporation | N-acyl and desamino human calcitonin and analogs thereof |
| US3980764A (en) * | 1973-11-05 | 1976-09-14 | Curtis Nuclear Corporation | Polymeric competitive protein binding adsorbents for radioassey |
| US4042677A (en) * | 1974-08-29 | 1977-08-16 | Union Carbide Corporation | Technetium-99m labeled radiodiagnostic agents and method of preparation |
| DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
| US4001200A (en) * | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
| US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
| US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
| US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
| DE2740053A1 (de) * | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
| DE2843963A1 (de) * | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin |
| JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4769326A (en) * | 1980-02-29 | 1988-09-06 | The Regents Of The University Of California | Expression linkers |
| US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| EP0039179B1 (de) * | 1980-04-28 | 1985-07-24 | National Research Development Corporation | Poröses Glas |
| JPS5716815A (en) * | 1980-07-02 | 1982-01-28 | Ajinomoto Co Inc | Oxygen transporting agent for artificial blood |
| US4551433A (en) * | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| US4374932A (en) * | 1981-06-08 | 1983-02-22 | G. D. Searle & Co. | 5-ASA Drug delivery system |
| JPS57206622A (en) * | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4500507A (en) * | 1981-10-30 | 1985-02-19 | Wong Dennis W | Diagnostic composition for radiologic imaging of neoplasms in the body and method of preparation |
| DE3144705C2 (de) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
| US4540564A (en) * | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
| IT1153000B (it) * | 1982-07-01 | 1987-01-14 | Resem Spa | Dispersioni acquose di poliuretani da oligouretani aventi gruppi terminali insaturi |
| US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4599197A (en) * | 1982-12-22 | 1986-07-08 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4713339A (en) * | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| GB8328917D0 (en) * | 1983-10-28 | 1983-11-30 | Fisons Plc | Blood substitute |
| US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US4738952A (en) * | 1984-04-27 | 1988-04-19 | Synthetic Blood Corporation | Substitute for human blood and a method of making the same |
| GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
| US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
| US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US4625014A (en) * | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| JPS6191131A (ja) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | 医薬品の吸着防止方法および組成物 |
| US4774180A (en) * | 1986-02-26 | 1988-09-27 | Massachusetts Institute Of Technology | Construction and application of polyproteins |
| JPH0732718B2 (ja) * | 1985-01-18 | 1995-04-12 | クマ−ル ガウリ，カイラツシユ | 蛋白加水分解物およびその製造法 |
| US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| DE3515252C2 (de) * | 1985-04-27 | 1994-02-24 | Roehm Gmbh | Verfahren zur Immobilisierung gelöster Eiweißstoffe |
| SE456136B (sv) * | 1985-06-17 | 1988-09-12 | Oncholab Ab | Forfarande for framstellning av en med ett lipofilt biologiskt aktivt emne bemengd berare pa basis av rekonstituerat ldl (lagdensitetslipoprotein) |
| EP0206448B1 (de) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist |
| AU6408586A (en) * | 1985-10-03 | 1987-04-24 | Biotechnology Research Partners Limited | Novel lipoprotein-based drug-delivery systems |
| US4783529A (en) * | 1985-12-03 | 1988-11-08 | Research Corporation Technologies | Rapid synthesis of radiolabeled porphyrin complexes for medical application |
| US4849142A (en) * | 1986-01-03 | 1989-07-18 | Jupiter Technologies, Inc. | Superplastic forging of zirconia ceramics |
| US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4730936A (en) * | 1986-10-10 | 1988-03-15 | The United States Of America As Represented By The Secretary Of The Air Force | Gas driven system for preparing large volumes of non-oxidized, pyridoxylated, polymerized stroma-free hemoglobin solution for use as a blood substitute |
| DE3636590A1 (de) * | 1986-10-28 | 1988-05-26 | Braun Melsungen Ag | Blutersatzmittel |
| DE3702105A1 (de) * | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| WO1988006601A1 (en) * | 1987-03-02 | 1988-09-07 | Genex Corporation | Gene repressors |
| GB8711614D0 (en) | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
| US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
| US5049493A (en) * | 1987-10-23 | 1991-09-17 | California Institute Of Technology | Enhancement of cell growth by expression of a cloned hemoglobin gene |
| EP0319206A3 (de) * | 1987-11-30 | 1990-04-18 | Berlex Laboratories, Inc. | Gen-Vermehrung |
| JP2561122B2 (ja) * | 1988-04-13 | 1996-12-04 | 寳酒造株式会社 | 機能性ポリペプチド |
| JP2983224B2 (ja) * | 1988-04-14 | 1999-11-29 | インサイト ファーマシューティカルズ，インコーポレイテッド | 哺乳動物の１４―β―ｇａ１レクチン類 |
| US5137819A (en) * | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
| IL87708A (en) * | 1988-09-08 | 1994-04-12 | Technion Inst For Research And | Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof |
| ZA902949B (en) * | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
| US5599907A (en) * | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
| DE69034091T2 (de) * | 1989-05-10 | 2004-04-22 | Baxter Biotech Technology S.A.R.L. | Herstellung von Hämoglobin und Analogen davon in Nicht-Erythrozytzellen |
| NL8901174A (nl) * | 1989-05-10 | 1990-12-03 | Het Hoofd Van De Afdeling Mili | Hemoglobine-preparaat en gebruik daarvan. |
| FR2650598B1 (fr) * | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
| JP2829397B2 (ja) * | 1989-10-09 | 1998-11-25 | 寳酒造株式会社 | フィブリン結合活性ポリペプチド |
| US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| DE3938953A1 (de) * | 1989-11-24 | 1991-05-29 | Max Planck Gesellschaft | Klonierung und expression des fuer die blut-hirn-schranke spezifischen proteins ht7 |
| DK608589D0 (da) * | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
| WO1991009134A1 (en) * | 1989-12-15 | 1991-06-27 | Takeda Chemical Industries, Ltd. | Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics |
| US5250665A (en) * | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
| JP3426599B2 (ja) * | 1991-11-08 | 2003-07-14 | ヘモゾル インコーポレイテッド | 薬物担体としてのヘモグロビン |
-
1992
- 1992-11-06 JP JP50878193A patent/JP3426599B2/ja not_active Expired - Lifetime
- 1992-11-06 EP EP92925154A patent/EP0611306B1/de not_active Expired - Lifetime
- 1992-11-06 WO PCT/US1992/009713 patent/WO1993008842A1/en active IP Right Grant
- 1992-11-06 AU AU31324/93A patent/AU665599B2/en not_active Ceased
- 1992-11-06 DE DE69226197T patent/DE69226197T2/de not_active Expired - Lifetime
- 1992-11-06 CA CA002122717A patent/CA2122717C/en not_active Expired - Lifetime
- 1992-11-06 US US08/240,711 patent/US5679777A/en not_active Expired - Lifetime
- 1992-11-06 AT AT92925154T patent/ATE168014T1/de not_active IP Right Cessation
-
1995
- 1995-06-01 US US08/457,753 patent/US5759517A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU665599B2 (en) | 1996-01-11 |
| CA2122717C (en) | 2003-07-15 |
| EP0611306B1 (de) | 1998-07-08 |
| ATE168014T1 (de) | 1998-07-15 |
| JPH07500840A (ja) | 1995-01-26 |
| US5759517A (en) | 1998-06-02 |
| US5679777A (en) | 1997-10-21 |
| AU3132493A (en) | 1993-06-07 |
| DE69226197D1 (de) | 1998-08-13 |
| WO1993008842A1 (en) | 1993-05-13 |
| EP0611306A1 (de) | 1994-08-24 |
| CA2122717A1 (en) | 1993-05-13 |
| JP3426599B2 (ja) | 2003-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69226197T2 (de) | Hämoglobine als arzneimittelabgabesystem | |
| IL93983A0 (en) | Method for enhanced transmembrane transport of exogenous molecules | |
| EA199800946A1 (ru) | Концентрированный препарат антител | |
| MX9605940A (es) | Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
| DE69200490D1 (de) | Tischgestell für medizinische Untersuchung. | |
| FR2649613B1 (fr) | Medicament vaso-actif | |
| ATA84882A (de) | Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut | |
| GR3026658T3 (en) | Hydrazino-type radionuclide chelators having an n 3?s configuration | |
| DK0600930T3 (da) | Diagnose og behandling af autoimmune sygdomme | |
| SV1998000122A (es) | Medicamentos ref. pu 3375/sv | |
| DE68906153D1 (de) | Humanes relaxinpraeparat. | |
| WO1992019213A3 (en) | Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy | |
| FI950062A0 (fi) | Proteiinien foroaktivaatio konjugaatiotarkoituksia varten | |
| DE68909409T2 (de) | Heilmitteldosierung zur verabreichung an fische. | |
| DE3882157D1 (de) | Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen. | |
| SE8602743L (sv) | Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid | |
| SE9402880D0 (sv) | New peptide derivatives | |
| SE8404283L (sv) | Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar | |
| ES2107431T3 (es) | Agentes con accion selectiva sobre los receptores de la adenosina. | |
| IT1226072B (it) | Soluzioni iniettabili pronte all'uso contenenti un glicoside antraciclinico antitumorale. | |
| DK0649433T3 (da) | Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne. | |
| ES2038064B1 (es) | Instalacion portatil de vacunacion aviar. | |
| ATE59550T1 (de) | Chlorpheniramine therapie. | |
| SE8204871L (sv) | Farmaceutiska preparat, innefattande humant proinsulin | |
| IT8467927A1 (it) | Preparati farmaceutici a base di dobutamina somministrabili por via orale. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: BAXTER BIOTECH TECHNOLOGY S.A.R.L., NEUCHATEL, CH |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: HEMOSOL INC., ETOBICOKE, ONTARIO, CA |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: THERAPURE BIOPHARMA INC., MISSISSAUGA, ONTARIO, CA |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: REHBERG HUEPPE + PARTNER, 37073 GOETTINGEN |
|
| R071 | Expiry of right |
Ref document number: 611306 Country of ref document: EP |